Clinical dimensions along the non-fluent variant primary progressive aphasia spectrum

“Clinical dimensions along the nonfluent variant primary progressive aphasia spectrum” Dr. Ignacio Illán Gala is a Neurologist at the memory unit of the Hospital de la Santa Creu i Sant Pau. He currently leads the research group focused on the “Natural history, diagnosis and treatment of Frontotemporal Lobar Degeneration”. Other clinical researchers from our center … Read more

Why study sex differences in Alzheimer’s disease and in the context of Down syndrome?

Why study sex differences in Alzheimer’s disease and in the context of Down syndrome?

Why study sex differences in Alzheimer’s disease and in the context of Down syndrome? The topic of sex differences is increasingly recognized as a top priority in neurology research, particularly in the context of precision medicine and personalized care strategies. Women account for around two-thirds of patients with Alzheimer’s disease, as well as their caregivers. … Read more

Cross-sectional versus longitudinal cognitive assessments for the diagnosis of symptomatic Alzheimer’s disease in adults with Down syndrome

Cross-sectional versus longitudinal cognitive assessments for the diagnosis of symptomatic Alzheimer's disease in adults with Down syndrome

Cross-sectional versus longitudinal cognitive assessments for the diagnosis of symptomatic Alzheimer’s disease in adults with Down syndrome Individuals with Down syndrome are at a high risk of developing the clinical symptoms of Alzheimer’s disease in old age due to the triplicating of chromosome 21. However, the clinical diagnosis of this disease is challenging, mainly due … Read more

GFAP in plasma and CSF in Down syndrome and Alzheimer’s disease

gfap - Sant Pau Memory Unit - Montoliu-Gaia - Alcolea

Alzheimer’s Disease, Down Syndrome and GFAP People with Down syndrome are at higher risk of developing Alzheimer’s disease than the general population. In fact, by the age of 70, more than 95% of people with Down syndrome will develop Alzheimer’s disease, which is the leading cause of death in this population. This strong association is … Read more

Blood Biomarkers in Neurodegenerative Diseases: Implications for the Clinical Neurologist

blood-based biomarkers in neurodegenerative diseases

Neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease, and frontotemporal dementia, are a growing health concern worldwide, and their diagnosis and management are still challenging. However, recent advances in blood-based biomarkers offer new opportunities for clinical evaluation and monitoring of these diseases. In this review article, entitled “Blood Biomarkers in Neurodegenerative Diseases: Implications for the … Read more

The Alzheimer’s Association has awarded 3 competitive projects to our unit

Memory Unit Photo 2022

The Alzheimer’s Association has awarded 3 competitive projects to our unit. The funded projects have been the following:   Role of synaptic miRNA and astrocyte miRNA delivery in Alzheimer’s disease (AARG-22-974373) led by Dr Olivia Belvin Alzheimer’s disease (AD) may be driven by a perturbance of small molecules (microRNAs) at neuronal junctions in the brain … Read more